CDER Reorganization Takes Effect, With Renamed Offices
This article was originally published in The Pink Sheet Daily
Executive Summary
Safety functions and Critical Path activities are the focus of new CDER offices.
You may also be interested in...
Gottlieb Promotes 'Team' Work For Product Reviews
US FDA Commissioner intends to change agency's siloed structure and move reviewers into teams that will follow products pre- and post-market.
Sweeping Changes At CDER Recommended In IoM Drug Safety Report
Among solutions suggested is six-year fixed term for the FDA commissioner and appointment of external advisory board to oversee cultural changes.
Sweeping Changes At CDER Recommended In IoM Drug Safety Report
Among solutions suggested is six-year fixed term for the FDA commissioner and appointment of external advisory board to oversee cultural changes.